Document Information Page

This page is for FDA internal use only. Do NOT send this page with the letter.

NDA 20-560/S-036
Supplement Letter
Approval Letters
Approval letter based on enclosed/submitted labeling text
SNDA-I1
AP: APPROVAL
RHedin/July 23, 2002
N20560AP_Lt25
If this is the first action on the application, link the outgoing letter to the initial
submission, RS, AR, or FO coded incoming document for the supplement being acted on,
as appropriate. Otherwise, the outgoing letter must be linked to the major amendment
submitted in response to the previous action letter.
In addition, the outgoing document should also be linked to all associated amendments and correspondences included in the action.

END OF DOCUMENT INFORMATION PAGE

The letter begins on the next page.



Food and Drug Administration Rockville MD 20857

NDA 20-560/S-036

Merck & Co., Inc.

Attention: Michele Flicker, M.D., Ph.D.

Director, Regulatory Affairs

P.O. Box 2000

Mail Drop: Ry 33-720 Rahway, NJ 07065

Dear Dr. Flicker:

Please refer to your supplemental new drug application dated February 15, 2002, received February 19, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Fosamax (alendronate sodium) Tablets.

We acknowledge receipt of your submission dated March 8, 2002.

This supplemental application, submitted as a "Supplement - Changes Being Effected" supplement, proposes alternative ("push-through" design) packaging to the currently approved 35 and 70 mg once weekly tablet 4-count trade bifold packaging ("peel-push" design). The "push-through" design blister is identical to the design of the approved 1-count sample package approved with supplements -021 and -022.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (text for the 35, and 70 mg strength 4-count trade bifold blister packages submitted February 15, 2002). Accordingly, the supplemental application is approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2 FDA 5600 Fishers Lane Rockville, MD 20857 We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.


If you have any questions, call Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.


Sincerely,


{See appended electronic signature page}


Sheldon Markofsky, Ph.D.
Acting Chemistry Team Leader II, DNDC II for the
Division of Metabolic and Endocrine Drug Products
Office of New Drug Chemistry
Center for Drug Evaluation and Research

Enclosure









This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Sheldon Markofsky 8/5/02 02:11:31 PM